Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00602667 · ClinicalTrials.gov registry record · Phase 2

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by St. Jude Children's Research Hospital.

Active
Registry status
Phase 2
Development phase
293
Enrollment target
6
Study locations

NCT00602667 is a Phase 2 study of Brain and Central Nervous System Tumors that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 293 participants, above the 177-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (66% higher). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00602667, a Phase 2 study of Brain and Central Nervous System Tumors, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
293 participants
Enrollment target
6
Study locations

Study Summary

RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important part of the two clinical trials which resulted in the best survival results for children less than 3 years of age with medulloblastoma. Most patients treated on this trial will also receive radiation which is carefully targeted to the area of the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in fewer problems with thinking and learning than radiation to the whole brain and spinal cord. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system tumors.

Interventions

  • DRUG Induction Chemotherapy
  • DRUG Low-Risk Therapy
  • DRUG High-Risk Therapy
  • DRUG Intermediate-Risk Therapy

Study Locations (6)

California

  • Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
  • Rady Children's Hospital - San Diego

Minnesota

  • Children's Hospitals and Clinics of Minnesota - St. Paul - Saint Paul

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Texas

  • University of Texas Southwestern Medical Center at Dallas - Dallas

Queensland

  • Lady Cilento Children's Hospital, Brisbane - Brisbane

Trial Details

FieldValue
Enrollment Target 293 participants
Start Date 2007-12-17
Est. Completion 2026-04
Phase Phase 2

What the Registry Record Tells You About NCT00602667

The ClinicalTrials.gov registry entry for NCT00602667 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (66% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 4 interventions - of which Induction Chemotherapy is the first listed.

NCT00602667 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Minnesota, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00602667 about?

NCT00602667 is a clinical study titled "Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma". RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important par...

What is the current status of trial NCT00602667?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2007-12-17. Estimated completion is 2026-04.

What conditions does trial NCT00602667 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00602667?

The interventions under investigation include: Induction Chemotherapy (DRUG), Low-Risk Therapy (DRUG), High-Risk Therapy (DRUG), Intermediate-Risk Therapy (DRUG).

Who is sponsoring clinical trial NCT00602667?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00602667 being conducted?

This trial has 6 study locations across California, Minnesota, Tennessee, Texas, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.